CVS Caremark Zepbound Coverage Is Back: What to Do Now

CVS Caremark Zepbound coverage is back. Effective October 1, 2026, Zepbound (tirzepatide) returns to CVS Caremark’s standard commercial formularies as a preferred option, sitting alongside Wegovy instead of being replaced by it. If you were forced to switch to Wegovy in mid-2025, or you have been paying cash for Zepbound ever since, this is the change you have been waiting for. Here is what changed, who it applies to, and what to do if your pharmacy still says “not covered.”

Updated September 30, 2026.

The short version:

• Is CVS Caremark covering Zepbound again? Yes, from October 1, 2026, on its standard commercial formularies.
• Is it automatic? No. Your employer or plan has to follow the updated formulary, and you will almost certainly need a new prior authorization.
• Do you have to leave Wegovy? No. Wegovy stays preferred too.

What changed with CVS Caremark Zepbound coverage in 2026?

A quick recap. In May 2025, CVS Caremark announced it was dropping Zepbound from its most common commercial formularies effective July 1, 2025, and making Wegovy (semaglutide) the preferred GLP-1 for weight management. Roughly 25 to 30 million members were affected, and many people on Zepbound had to switch to Wegovy, appeal, or pay out of pocket.

On May 28, 2026, CVS Health announced a reversal. The key points:

• Zepbound is back as of October 1, 2026 as an additional preferred option on CVS Caremark’s template commercial formularies.
• Wegovy stays preferred too, both the injection and the Wegovy pill. If you are stable on Wegovy, nothing forces you to move.
• Foundayo (orforglipron), Lilly’s daily GLP-1 pill, had its new-to-market block removed on June 1, 2026, where plans approve coverage.
• Same tier, no penalty. For participating plans, Zepbound and Wegovy sit at the same formulary tier, so choosing one over the other should not cost you a higher copay.

The reason, according to CVS, is a new pricing agreement with Eli Lilly. After a year of negotiations, the cost came down enough for Caremark to put both brands back on the list.

Does the new CVS Caremark Zepbound coverage apply to you?

This is the part most headlines skip. CVS Caremark is a pharmacy benefit manager, not your insurance plan. It builds template formularies, but your employer or health plan chooses whether to adopt them and can customize coverage. So the October 1 change applies if:

• Your prescription benefits are managed by CVS Caremark (check your pharmacy card or the Caremark app).
• Your plan uses one of Caremark’s standard commercial formularies, such as Standard Control, Advanced Control, or Value.
• Your plan covers weight-management GLP-1s at all. Many employers exclude the whole category, and this announcement does not change that. If your plan is cutting the benefit for next year, see what to do when your employer drops GLP-1 coverage in 2027.

Medicare plans work differently. If you are on Medicare Part D, the relevant program is the Medicare GLP-1 Bridge, which offers a $50 monthly copay for eligible beneficiaries from July 1, 2026 through December 31, 2027.

The easiest way to confirm: log in to Caremark.com or the app, use the “Check Drug Cost” tool for Zepbound, and look at the coverage status. If it still shows as not covered, work through the checklist below.

Zepbound still showing “not covered”? Five things to check

A rejection at the pharmacy counter after October 1 does not always mean your plan opted out. In most cases it is one of these, and the first two are fixable within days:

• No prior authorization on file yet. If the rejection says “prior authorization required,” the drug is on your formulary. Your prescriber simply needs to submit the form.
• Your old approval does not carry over. A Zepbound PA from before July 2025 has usually expired, and a current Wegovy PA does not transfer to Zepbound. Expect a fresh request with up-to-date chart notes.
• Your plan has not adopted the update. Employers with a custom formulary can stay Wegovy-only or pick their own timing. Call the member number on your card and ask, “Has my plan adopted the October 2026 formulary change for Zepbound?” If the answer is no, ask HR whether it is planned for the 2027 plan year. Open enrollment is the moment to push on this.
• Your plan excludes weight-loss medications. A category exclusion overrides the formulary. Ask whether the exclusion also applies to Zepbound’s sleep apnea indication, which some plans treat separately.
• Step therapy is still in place. Some plans required a trial of Wegovy first during the gap. Ask whether that rule still applies, and whether your time on Wegovy already satisfies it.

If the PA itself is denied, you have the right to appeal. Our guide to appealing a Wegovy or Zepbound denial walks through the evidence and the letter.

Prior authorization: what to expect

Coverage returning does not mean automatic approval. Nearly every plan that covers Zepbound requires prior authorization (PA), a form your prescriber submits showing you meet the plan’s criteria. Typical requirements include:

• A BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, sleep apnea, or type 2 diabetes.
• Documentation of a lifestyle program (diet and exercise) alongside the medication.
• For renewals, proof of response, often a 5% weight loss from your starting weight.

If you were on Zepbound before the 2025 change, ask your provider’s office whether your earlier weight history can be attached to the new request. Your logged weights from the past year are useful evidence here, especially your starting weight before any GLP-1. If you have been keeping a weight and dose history, export it and bring it to the appointment. You can track all of it free with Pep, which stores your dose log, weight trend, and side-effect notes in one place so the paperwork takes minutes instead of an afternoon of digging through old texts and photos.

Switching back from Wegovy to Zepbound

If you moved to Wegovy in 2025 and want to return to Zepbound, here is what to know. First, there is no official one-to-one dose conversion between semaglutide and tirzepatide. They are different molecules with different dose ladders: Wegovy runs 0.25, 0.5, 1, 1.7, and 2.4 mg weekly (plus the newer 7.2 mg Wegovy HD), while Zepbound runs 2.5, 5, 7.5, 10, 12.5, and 15 mg weekly. Your prescriber will choose a Zepbound starting dose based on your history, your current tolerance, and how much appetite control you have. Some people go back to a dose near where they left off; others restart lower to limit nausea.

A few practical tips for the transition:

• Do not overlap doses. Both are once-weekly injections, and the usual approach is to take Zepbound when your next Wegovy dose would have been due. Confirm the timing with your prescriber or pharmacist.
• Expect a side-effect reset. Even at a familiar dose, switching molecules can bring back early-weeks nausea, fatigue, or constipation for a couple of weeks. Our guides on reducing nausea and constipation relief cover the basics.
• Map out the ladder. If you are restarting at a lower dose, the free GLP-1 dose schedule calculator shows when each step-up could land so you know what to expect month by month.
• Log the switch date. Note the last Wegovy dose and first Zepbound dose. If side effects or a plateau show up later, the timeline makes the cause obvious to you and your provider.

For a deeper comparison of the two medications, including trial results and typical weight loss, see Zepbound vs Wegovy.

What Zepbound costs once coverage is active

Your exact copay depends on your plan’s tier structure, but here are the numbers to know:

• Lilly’s Zepbound savings card can bring the cost down to as little as $25 for a one-, two-, or three-month fill if you have commercial insurance that covers Zepbound. Savings are capped at about $100 per month and $1,300 per calendar year, so a high copay may leave a balance. The current card runs through December 31, 2026, and it does not work with Medicare, Medicaid, VA, or TRICARE. Check Lilly’s savings page for the latest terms.
• Self-pay Zepbound through LillyDirect runs $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and up, as long as you refill within 45 days. That is the fallback if your plan opts out.
• Wegovy self-pay is currently $349 a month for the injection and less for the pill, which matters if you are weighing whether switching back is worth it.

To compare scenarios side by side, plug your plan’s copay and the self-pay options into the GLP-1 cost calculator, and see our full breakdown of what GLP-1s cost in 2026.

Your action plan from October 1

• This week: Run Zepbound through the “Check Drug Cost” tool in the Caremark app. Then message your prescriber and ask them to submit the Zepbound prior authorization. Gather your weight and dose history to attach.
• While the PA is pending: Stay on your current medication so there is no gap in treatment. Register for the Lilly savings card so it is ready for your first fill.
• At the pharmacy: If the claim rejects, ask for the exact reason. A PA issue is fixable, while a plan exclusion is a conversation with HR.
• First 4 weeks on Zepbound: Log each dose, your weekly weight, and any side effects so you and your provider can judge the transition with real data instead of memory.

The 2025 formulary change caused a surge of medication switching: Truveta data presented in 2026 showed monthly switching away from tirzepatide jumped roughly 17-fold in the months after the change. Expect a similar wave in the other direction this fall, which means pharmacy and PA backlogs. Therefore, getting the paperwork in early is the best way to avoid a gap in treatment.

CVS Caremark Zepbound coverage FAQ

Is CVS Caremark covering Zepbound again in 2026?

Yes. CVS Caremark Zepbound coverage returned on October 1, 2026, for commercial plans that use Caremark’s standard template formularies and cover weight-management GLP-1s. Individual plan sponsors can customize coverage, so confirm with your plan.

Do I have to switch from Wegovy back to Zepbound?

No. Wegovy injection and the Wegovy pill remain preferred on CVS Caremark formularies, and members currently on Wegovy can continue without interruption. Switching is a choice you and your prescriber make, not a requirement.

Will CVS Caremark Zepbound coverage require prior authorization?

Almost certainly. Most plans require a PA confirming BMI criteria and a lifestyle program, and renewals often require documented weight loss. An old Zepbound approval or a current Wegovy approval will not carry over, so ask your prescriber to submit a new request.

Why does Zepbound still show as not covered by Caremark?

The most common reasons are a missing prior authorization, a plan that has not adopted the updated formulary, or a plan-wide exclusion for weight-loss medications. Ask the pharmacy for the rejection reason, then call the member number on your card.

This article is for educational purposes only and is not medical or insurance advice. Coverage details vary by plan; confirm with CVS Caremark, your plan sponsor, and your healthcare provider.